Program
Anti-CCR8 Antibody-drug Conjugate TAK-188
Its studies are led by Takeda.
Furthest: phase 2, since Sep 26, 20251 company-led study, 1 open or runningNext primary completion: Dec 26, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 11 open or running | phase 2since Sep 26, 2025 | Sep 26, 2025 | Dec 26, 2028phase 2 · NCT07205718 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 26, 2025First study: phase 2 study in Advanced or Metastatic Solid TumorsFirst studyNCT07205718 · 273 planned · United States
Ahead
- Dec 26, 2028Primary completion: phase 2 study in Advanced or Metastatic Solid TumorsNCT07205718
TargetBeta
CCR8 →read by rule
“An antibody-drug conjugate (ADC) composed of an antibody directed against human C-C motif chemokine receptor 8 (CCR8) ”NCIt, by rule
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 7 |
| CCR8 Inhibitor IPG7236rule | nanjing-immunophage-biotech-co-ltd | phase 2 | 3 |
| denikitugrule | Gilead Sciences | phase 2 | 3 |
| tagmokitugrule | coherus-oncology-inc | phase 2 | 3 |
| imzokitug | Bristol-Myers Squibb | phase 2 | 2 |
| Anti-CCR8 Monoclonal Antibody HC006rule | hc-biopharma-inc | phase 1 | 2 |
| azirkitug | AbbVie | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07205718Advanced or Metastatic Solid Tumors · United States | 2 | Recruiting | Dec 26, 2028 | 273 |
How it is read
Names in the registry
- “TAK-188”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.